These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 19271275)

  • 1. Rosuvastatin in patients with elevated C-reactive protein.
    Jenny-Avital ER
    N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271275
    [No Abstract]   [Full Text] [Related]  

  • 2. Rosuvastatin in patients with elevated C-reactive protein.
    Chan PS; Nallamothu BK; Hayward RA
    N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271273
    [No Abstract]   [Full Text] [Related]  

  • 3. Rosuvastatin in patients with elevated C-reactive protein.
    Koller MT; Bucher HC; Steyerberg EW
    N Engl J Med; 2009 Mar; 360(10):1041; author reply 1041-2. PubMed ID: 19271276
    [No Abstract]   [Full Text] [Related]  

  • 4. JUPITER study highlights value of anti-inflammatory action of rosuvastatin.
    Cardiovasc J Afr; 2009; 20(3):211. PubMed ID: 19575096
    [No Abstract]   [Full Text] [Related]  

  • 5. Rosuvastatin in patients with elevated C-reactive protein.
    Pierard LA
    N Engl J Med; 2009 Mar; 360(10):1040; author reply 1041-2. PubMed ID: 19271277
    [No Abstract]   [Full Text] [Related]  

  • 6. Rosuvastatin in patients with elevated C-reactive protein.
    Gibbons RJ
    N Engl J Med; 2009 Mar; 360(10):1038; author reply 1041-2. PubMed ID: 19264695
    [No Abstract]   [Full Text] [Related]  

  • 7. [Statin cuts cardiovascular risk in half].
    Einecke D
    MMW Fortschr Med; 2008 Dec; 150(49-50):12-3. PubMed ID: 19133364
    [No Abstract]   [Full Text] [Related]  

  • 8. [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor].
    Olsson AG
    Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1471-5. PubMed ID: 19579435
    [No Abstract]   [Full Text] [Related]  

  • 9. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.
    Ridker PM;
    Circulation; 2003 Nov; 108(19):2292-7. PubMed ID: 14609996
    [No Abstract]   [Full Text] [Related]  

  • 10. [Less vascular risk with rosuvastatin in elevated CRP].
    Bredie B
    Ned Tijdschr Geneeskd; 2009 Feb; 153(6):245. PubMed ID: 19271446
    [No Abstract]   [Full Text] [Related]  

  • 11. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA
    Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The JUPITER Trial: responding to the critics.
    Ridker PM; Glynn RJ
    Am J Cardiol; 2010 Nov; 106(9):1351-6. PubMed ID: 21029837
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular health. Statin therapy reduces disease in healthy volunteers--but how, exactly?
    Couzin J
    Science; 2008 Nov; 322(5904):1039. PubMed ID: 19008423
    [No Abstract]   [Full Text] [Related]  

  • 14. Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    Sniderman AD
    Lancet; 2009 Jul; 374(9683):25; author reply 26-7. PubMed ID: 19577690
    [No Abstract]   [Full Text] [Related]  

  • 15. [JUPITER study (2). For now no reason to give statins to more people].
    Koopmans RP
    Ned Tijdschr Geneeskd; 2009 Feb; 153(6):218-9. PubMed ID: 19271439
    [No Abstract]   [Full Text] [Related]  

  • 16. Low-risk older patients (50 years and older) with raised high-sensitivity CRP (hs-CRP) benefit from rosuvastatin therapy: the JUPITER study.
    Cardiovasc J Afr; 2008; 19(6):332-4, discussion 335. PubMed ID: 19104734
    [No Abstract]   [Full Text] [Related]  

  • 17. [JUPITER no support of changed guidelines for cardiovascular prevention. Moderate absolute risk reduction and uncertain long term effects].
    Håkansson J
    Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1460-1. PubMed ID: 19579433
    [No Abstract]   [Full Text] [Related]  

  • 18. Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    de Tena JG
    Lancet; 2009 Jul; 374(9683):24; author reply 26-7. PubMed ID: 19577686
    [No Abstract]   [Full Text] [Related]  

  • 19. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
    Fonseca FA; Izar MC
    Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The editor's roundtable: the JUPITER trial--initial results and clinical implications.
    Ridker PM; Friedewald VE; Davidson MH; Willerson JT; Roberts WC
    Am J Cardiol; 2009 May; 103(10):1417-25. PubMed ID: 19427439
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.